Reports Q4 revenue $68.7M, consensus $67.19M.New active surgeon additions of 280 for full-year 2024; ended the year with 3,135 active surgeons, a 10% increase compared to the prior year.Expanded global patent portfolio now includes 97 granted patents and 88 pending patent applications..”We continued to execute on our strategic plan, launching multiple new technologies while improving profitability, positioning us well for continued growth in 2025 and beyond,” said John T. Treace, CEO, Founder and Board Member of Treace. “We are excited to enter 2025 with our expanded bunion portfolio and look forward to delivering additional innovations to address the evolving needs of our surgeon customers, positioning us to drive further penetration in the bunion market.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMCI:
- Treace Medical upgraded to Buy from Neutral at BTIG
- Treace Medical announces completion of first cases using SpeedAkin ACI
- Treace Medical ‘a rarer asset’ after Zimmer buys Paragon 28, says Lake Street
- Treace Medical Concepts Reports Strong 2024 Revenue Growth
- Treace Medical reports preliminary Q4 revenue $68.4M-$68.8M, consensus $67.02M